Clinical Trials on NMOSD in Japan

Total 2 results

Hoffmann-La Roche
Chugai Pharmaceutical Co.

Terminated

A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention (SAkuraBonsai)

Neuromyelitis Optica Spectrum Disorder | NMOSD

United States, Korea, Republic of, Italy, Canada, Japan, Turkey
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

Spain, Italy, United States, Japan, Poland, Taiwan, Germany, United Kingdom, Hungary, France, Ukraine

3

Subscribe